The Politics Of Avandia: CDER Memos Reveal Frustration With External Pressure

FDA internal memos released in connection with the agency’s regulatory decision on GlaxoSmithKline PLC’s Avandia reflect Center for Drug Evaluation and Research officials’ frustration with the spotlight under which they have been operating for the past three years to evaluate rosiglitazone’s cardiovascular risks.